Parallax Volatility Advisers’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-50,000
| Closed | -$2.01M | – | 1519 |
|
|
2026
Q1 | $2.01M | Sell |
50,000
-74,000
| -60% | -$1.59M | 0.01% | 784 |
|
|
2025
Q4 | $3.11M | Hold |
124,000
| – | – | 0.01% | 820 |
|
|
2025
Q3 | $2.81M | Hold |
124,000
| – | – | ﹤0.01% | 824 |
|
|
2025
Q2 | $2.15M | Hold |
124,000
| – | – | ﹤0.01% | 857 |
|
|
2025
Q1 | $2.71M | Sell |
124,000
-74,500
| -38% | -$2.06M | 0.01% | 783 |
|
|
2024
Q4 | $6.33M | Buy |
198,500
+49,500
| +33% | +$1.49M | 0.01% | 737 |
|
|
2024
Q3 | $4.3M | Buy |
+149,000
| New | +$5.52M | 0.01% | 853 |
|
|
2024
Q1 | – | Sell |
-27,700
| Closed | -$1.66M | – | 1805 |
|
|
2023
Q4 | $1.66M | Buy |
27,700
+21,500
| +347% | +$1.09M | ﹤0.01% | 1227 |
|
|
2023
Q3 | $236K | Sell |
6,200
-10,800
| -64% | -$474K | ﹤0.01% | 1776 |
|
|
2023
Q2 | $1.55M | Sell |
17,000
-61,500
| -78% | -$5.31M | ﹤0.01% | 1234 |
|
|
2023
Q1 | $5.18M | Sell |
78,500
-4,700
| -6% | -$271K | 0.01% | 843 |
|
|
2022
Q4 | $4.3M | Buy |
+83,200
| New | +$4.41M | 0.01% | 1089 |
|
|
2022
Q3 | – | Sell |
-135,700
| Closed | -$6.14M | – | 3041 |
|
|
2022
Q2 | $6.14M | Sell |
135,700
-14,300
| -10% | -$652K | 0.01% | 904 |
|
|
2022
Q1 | $7.62M | Buy |
150,000
+76,400
| +104% | +$3.37M | ﹤0.01% | 839 |
|
|
2021
Q4 | $3.48M | Sell |
73,600
-38,100
| -34% | -$1.5M | ﹤0.01% | 1363 |
|
|
2021
Q3 | $3.68M | Sell |
111,700
-25,800
| -19% | -$1.45M | ﹤0.01% | 1374 |
|
|
2021
Q2 | $8.69M | Buy |
+137,500
| New | +$7.1M | 0.01% | 949 |
|
|
2020
Q3 | – | Sell |
-25,800
| Closed | -$843K | – | 3027 |
|
|
2020
Q2 | $843K | Buy |
+25,800
| New | +$829K | ﹤0.01% | 1800 |
|
|
2020
Q1 | – | Sell |
-1,400
| Closed | -$43K | – | 2447 |
|
|
2019
Q4 | $43K | Buy |
+1,400
| New | +$38.7K | ﹤0.01% | 2229 |
|
Other funds holding APLS
Parallax Volatility Advisers's APLS Position: Q3 2025 in Review
Parallax Volatility Advisers sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 24,443 shares — an estimated $570K sold.
Parallax Volatility Advisers first reported a position in APLS in Q4 2017 and held it in 15 quarters. The position peaked at $5.27M in Q3 2022. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.
- Parallax Volatility Advisers reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Parallax Volatility Advisers sold 24,443 Apellis Pharmaceuticals shares in Q3 2025, an estimated $570K.
- Parallax Volatility Advisers first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 15 quarters.
- Parallax Volatility Advisers's Apellis Pharmaceuticals position peaked at $5.27M in Q3 2022.
- 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.
Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.